Selected Publications

Michael Sporn, M.D.

  1. Liby, K., Royce, D.B., Risingsong, R., Williams, C.R., Maitra, A., Hruban, R.H., Sporn, M.B. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res, in press, 2010.
  2. Yore, M.M., Kettenbach, A.N., Liby, K.T., Gerber, S.A., Sporn, M.B., Chemical proteomics reveals multiple cellular targets for synthetic oleanane triterpenoids. In preparation.
  3. Stack, C., Ho, D., Wille, E., Calingasan, N.Y., Williams, C., Liby, K., Sporn, M., Dumont, M., Beal, F. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radical Biology and Medicine, 49:147-158, 2010.
  4. Liby, K., Risingsong, R., Royce, D.B., Williams, C.R., Ma, T., Yore, M.M., and Sporn, M.B. Triterpenoids, CDDO-methylester or CDDO-ethylamide and rexinoids, LG 100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev Res, 2: 1050-1058, 2009.
  5. Sussan, T.E., Rangasamy, T., Blake, D.J. , Malhotra, D., El-Haddad, H., Bedja, D., Yates, M.S., Kombairaju, P., Yamamoto, M., Liby, K.T., Sporn, M.B., Gabrielson, K.L., Champion, H.C., Tuder, R.M., Kensler, T.W., and Biswal, S. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci USA, 106: 250-255, 2009.
  6. Yates, M.E., Tran, Q.T., Dolan, P.D., Osburn, W.O., Shin, S., McCulloch, C., Silkworth, J.B., Taguchi, K., Yamamoto, M., Williams, C.R., Liby, K.T., Sporn, M.B., Suttter, T.R., and Kensler, T.W. Genetic versus chemoprotective activation of Nrf2 signalling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid treated mice. Carcinogenesis, 30: 1024-1031, 2009.
  7. Sporn, M. B., Liby, K., Yore, M. M., Suh, N., Albini, A., Honda, T., Sundararajan, C., and Gribble, G. W. Platforms and networks in triterpenoid pharmacology. Drug Develop Res, 68: 174-182, 2007.
  8. Liby, K. T., Yore, M. M., and Sporn, M. B. Triterpenoids and rexinoids as multifunctional agents for prevention and treatment of cancer. Nature Reviews Cancer, 7: 357-369, 2007.
  9. Albini, A. and Sporn, M. B. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer, 7: 139-147, 2007.
  10. Suh, N., Wang, Y., Honda, T., Gribble, G. W., Dmitrovsky, E., Hickey, W. F., Maue, R. A., Place, A. E., Porter, D. M., Spinella, M. J., Williams, C. R., Wu, G., Dannenberg, A. J., Flanders, K. C., Letterio, J. J., Mangelsdorf, D. J., Nathan, C. F., Nguyen L., Porter, W. W., Ren, R. F., Roberts, A. B., Roche, N. S., Subbaramaiah, K., and Sporn, M. B. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), with potent differentiating, anti-proliferative, and anti-inflammatory activity. Cancer Res 59:336-341, 1999.
  11. Gudas, L. J., Sporn, M. B., and Roberts, A. B. Cellular biology and biochemistry of the retinoids. In The Retinoids: Biology, Chemistry, and Medicine, 2nd Edition (eds. M.B. Sporn, A.B. Roberts, D.S. Goodman), Raven Press Ltd., New York, NY, pp 443-520, 1994.
  12. Sporn, M. B. and Roberts, A. B. Interactions of retinoids and transforming growth factor-β (TGF-β) in regulation of cell differentiation and proliferation. Molec Endocrinol 5:3-7, 1991.
  13. Sporn, M. B. and Roberts, A. B. The multifunctional nature of peptide growth factors. In: Handbook of Experimental Pharmacology, "Peptide growth factors and their receptors,'' (eds. Sporn MB, Roberts AB) Springer-Verlag, Heidelberg. Vol. 95/1, pp 3-15, 1990.
  14. Sporn, M. B., Roberts, A. B., Wakefield, L. M., and de Crombrugghe, B. Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 105:1039-1045, 1987.
  15. Assoian, R. K., Komoriya, A., Meyers, C. A., and Sporn, M. B. Transforming growth factor-beta in human platelets: Identification of a major storage site, purification, and characterization. J Biol Chem 258:7155-7160, 1983.
  16. Sporn, M. B. and Todaro, G. J. Autocrine secretion and malignant transformation of cells. New Engl J Med 303:878-880, 1980.

Karen T. Liby, Ph.D.

  1. Liby KT, Dinkova-Kostova A, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW and Sporn MB. Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. PNAS 102:4584-9, 2005.
  2. Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A and Sporn MB. The synthetic triterpenoids, CDDO and CDDO-Imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65:4789-98, 2005.
  3. Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB and Letterio JJ. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res, 12:4288-93, 2006.
  4. Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, and Sporn MB. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either Arzoxifene or Acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Can Res, 12:5902-9, 2006.
  5. Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA and Sporn MB. The synthetic triterpenoids, CDDO-Methyl ester and CDDO-Ethyl amide, prevent lung cancer induced by vinyl carbamate in A/J mice. Can Res, 67:2414-9, 2007.
  6. Liby K, Yore MM and Sporn MB. Triterpenoids and rexinoids as multifunctional agents for prevention and treatment of cancer. Nat Rev Cancer, 7:357-69, 2007.
  7. Liby K, Royce DB, Risingsong R, Williams CR, Wood MD, Chandraratna RA and Sporn MB. NRX194204 prevents carcinogenesis in both the lung and mammary gland. Clin Can Res, 13:6237-43, 2007.
  8. Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, Honda T, Gribble GW, Lamp WW, Vannini N, Lorusso G, Albini A and Sporn MB. Prevention and treatment of experimental ER-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268. Clin Can Res, 14:4556-63, 2008.
  9. Liby K, Yore MM, Williams CR, Risingsong R, Royce DB, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, Gribble GW, Dinkova-Kostova AT, Stephenson KK, Talalay P, Egner PA, Yates MS, Kensler TW and Sporn MB. A multifunctional tricyclic bis-enone containing an acetylene group is a potent inducer of phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. Can Res, 68:6727-33, 2008.
  10. Liby K, Risingsong R, Royce DB, Williams CR, Ma T, Yore MM and Sporn MB. Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Can Prev Res, 2:1050-8, 2009.
  11. Liby K, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Can Prev Res, in press, 2010.

Mark Yore, Ph.D.

  1. Liby K, Risingsong R, Royce DB, Williams CW, Ma T, Yore MM and Sporn MB. Combinations of triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev Res. 2, 1050-8 (2009).
  2. Liby K †, Yore MM †, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, Yoshizawa H, Gribble GW, Williams CR, Risingsong R, Royce DB, Dinkova-Kostova AT, Stephenson KK, Egner PA, Yates MS, Groopman J, Kensler TW, Sporn MB. A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. Cancer Res. 68, 6727-33 (2008).
    † denotes co-first authorship
  3. Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, Honda T, Gribble GW, Lamph WW, Vannini N, Sogno I, Albini A, Sporn MB. Prevention and Treatment of Experimental Estrogen Receptor-Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268. Clin Cancer Res. 14, 4556-63 (2008).
  4. Liby K, Black CC, Royce D, Williams CW, Risingsong R, Yore MM, Liu Z, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E and Sporn MB. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are significantly more potent than erlotinib for prevention of lung carcinogenesis in A/J mice. Mol Cancer Ther. 5, 1251-7 (2008).
  5. Sporn MB, Liby K, Yore MM, Suh N, Albini A, Honda T, Sundararajan C & Gribble GW. Platforms and Networks in Triterpenoid Pharmacology. Drug Dev Res. 68, 174-182 (2007).
  6. Liby K, Yore MM, & Sporn MB. Triterpenoids and rexinoids as multifunctional agents for prevention and treatment of cancer. Nat Rev Cancer. 5, 357-69 (2007).
  7. Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, & Sporn MB. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 67, 2414-2419 (2007).
  8. Yore MM, Liby KT, Honda T, Gribble GW, & Sporn MB The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther. 5, 3232-3239 (2006).
  9. Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, Baumgartner KJ, Roebuck BD, Liby KT, Yore MM, Honda T, Gribble GW, Sporn MB, & Kensler TW. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res. 66, 2488-2494 (2006).
  10. Ogden SK, Casso DJ, Ascano M, Yore MM, Kornberg TB, & Robbins DJ. Smoothened regulates activator and repressor functions of Hedgehog signaling via two distinct mechanisms. J Biol Chem. 281, 7237-7243 (2006).
  11. Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, & Sporn MB The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 65, 4789-4798 (2005).
  12. White KA, Yore MM., Deng D, & Spinella MJ Limiting effects of RIP140 in estrogen signaling: potential mediation of anti-estrogenic effects of retinoic acid. J Biol Chem. 280, 7829-7835 (2005).
  13. White KA, Yore MM, Warburton SL, Vaseva AV, Rieder E, Freemantle SJ, & Spinella MJ Negative feedback at the level of nuclear receptor coregulation. Self-limitation of retinoid signaling by RIP140. J Biol Chem. 278, 43889-43892 (2003).

Charlotte Williams, B.S.

  1. Liby, K., Royce, D.B., Risingsong, R., Williams, C.R., Maitra, A., Hruban, R.H., Sporn, M.B. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res, in press, 2010.
  2. Honda, T., Padegimas, E.M., David, E. Sundararajan, C., Liby, K.T., Williams, C., Sporn, M.B., Visnick, M. 2-Cyano-3, 10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-imflammatory and cytoprotective agent. Bioorganic & Medicinal Chemistry Letters, 20: 2275-2278, 2010.
  3. Stack, C., Ho, D., Wille, E., Calingasan, N.Y., Williams, C., Liby, K., Sporn, M., Dumont, M., Beal, F. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of HuntingtonÕs disease. Free Radical Biology and Medicine, 49:147-158, 2010.
  4. Liby, K., Risingsong, R., Royce, D.B., Williams, C.R., Ma, T., Yore, M.M., and Sporn, M.B. Triterpenoids, CDDO-methylester or CDDO-ethylamide and rexinoids, LG 100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev Res, 2: 1050-1058, 2009.
  5. Yang, L., Calingasan, N.Y., Thomas, B., Chaturvedi, R.K., Kiaei, M., Wille, E.J., Liby, K.T., Willliams, C., Royce, D., Risingsong, R., Musiek, E.S., Morrow, J.D., Sporn, M., and Beal, M.F. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS ONE, 4: e5757, 2009.
  6. Dumont, M., Wille, E., Calingasan, N.Y., Tampellini, D., Williams, C., Gouras, G.K., Liby, K., Sporn, M., Nathan, C., Beal, M.F., and Lin, M.T. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of AlzheimerÕs disease. J Neurochem, 109: 502-512, 2009.
  7. Liby, K., Yore, M. M., Roebuck, B. D., Baumgartner, K. J., Honda, T., Sundararajan, C., Yoshizawa, H., Gribble, G. W., Williams, C. R., Risingsong, R., Royce, D. B., Dinkova-Kostova, A. T., Stephenson, K. K., Egner, P. A., Yates, M. S., Groopman, J. D., Kensler, T. W., and Sporn, M. B. A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. Cancer Res, 68: 6727-6733, 2008.
  8. Liby, K., Risingsong, R., Royce, D. B., Williams, C. R., Mark M. Yore, T. H., Gribble, G. W., Lamph, W. W., Vannini, N., Sogno, I., Albini, A., and Sporn, M. B. Prevention and treatment of experimental ER-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268. Clin Cancer Res, 14: 4556-4563, 2008.
  9. Liby, K., Black, C. C., Royce, D. B., Williams, C. R., Risingsong, R., Yore, M. M., Liu, X., Honda, T., Gribble, G. W., Lamph, W. W., Sporn, T. A., Dmitrovsky, E., and Sporn, M. B. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther, 7: 1251-1257, 2008.
  10. Liby, K., Royce, D. B., Risingsong, R., Williams, C. R., Wood, M. D., Chandraratna, R. A., and Sporn, M. B. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clin Cancer Res, 13: 6237-6243, 2007.